News of Note—Emergent’s new CEO, Valneva’s chikungunya vaccine and more

newspapers
(Pixabay)

Here is some other vaccine news of note for the week:

> Emergent BioSolutions announced that its CEO since 2012, Daniel J. Abdun-Nabi, will retire and be replaced by Robert G. Kramer, Sr., the company’s current president and COO, effective Apr. 1, 2019. Release

> Valneva reported positive phase 1 interim results for its chikungunya vaccine candidate, VLA1553, showing a single vaccination achieved a 100% seroconversion rate at Day 28. The news came as the company announced plans to delist from the Vienna Stock Exchange to focus trading on Euronext Paris. Release | Release

INDUSTRY RESEARCH

Veeva 2019 Unified Clinical Operations Survey

Share your thoughts in this quick survey. The first 50 qualified respondents will receive a $5 Amazon gift card, and, in appreciation for your time, all qualified survey respondents will be entered in a drawing to win a $50 Amazon gift card.

> Walter Ricciardi, president of Italy’s National Institute of Health, has resigned, accusing the League and Five Star Movement-led government’s antivaccine stance and other “unfounded” health claims. The BMJ article

> The Coalition for Epidemic Preparedness Innovations is making $48 million of funding available to support development of vaccines against Rift Valley fever and chikungunya. Release